ERAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Erasca Inc (ERAS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows bullish technical indicators, positive analyst sentiment, and a promising growth outlook in the RAS inhibitor space. Despite weak financials, the company's pipeline and analyst optimism outweigh the negatives for a long-term investor.
The technical indicators are bullish overall. The stock's moving averages (SMA_5 > SMA_20 > SMA_200) suggest an upward trend. The RSI is neutral at 76.536, and the MACD is slightly negative (-0.0657) but contracting, indicating potential for a reversal to the upside. The stock is trading near its resistance level (R1: 13.836), which could signal further upward movement.
Analysts have significantly raised price targets recently, with Guggenheim, Mizuho, and Piper Sandler assigning Buy or Outperform ratings.
Promising updates on ERAS-0015 and ERAS-4001, with potential commercial launches in
The RAS inhibitor portfolio is positioned for proof-of-concept in 2026, targeting large addressable markets.
Weak financial performance with no revenue and a net income loss of -$30.61M in Q3
Lack of recent news or event-driven catalysts.
No significant hedge fund or insider trading activity.
Erasca's financials are weak, with no revenue growth and a net income loss of -$30.61M in Q3 2025. EPS remains negative at -0.11. However, the company is in a development stage, and its future potential lies in its RAS-targeted pipeline.
Analyst sentiment is highly positive, with multiple firms raising price targets significantly (e.g., Guggenheim to $12, Mizuho to $16, Piper Sandler to $11). Analysts highlight the company's differentiated RAS-targeted pipeline and large market opportunities. However, some caution remains due to the early stage of clinical trials.
